Trial Profile
Efficacy of Canakinumab in Caucasian patients with Yao Syndrome: a retrospective, single centre study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2018
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Familial autosomal dominant periodic fever
- Focus Therapeutic Use
- 24 Nov 2018 New trial record
- 24 Oct 2018 Results assessing efficacy of canakinumab in patients with Yao syndrome, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.